BGB 3111

Drug Profile

BGB 3111

Alternative Names: BGB-3111

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator BeiGene
  • Developer BeiGene; Peter MacCallum Cancer Centre
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma

Most Recent Events

  • 06 Dec 2016 Updated efficacy and adverse event data from a phase I trial in B-cell Malignancies presented at 2016 American Society of Haematology (ASH-2016)
  • 07 Oct 2016 Updated interim efficacy and adverse event data from a phase I trial in B-cell lymphoma (Second-line therapy or greater, Monotherapy) released by BeiGene
  • 07 Oct 2016 BeiGene plans a phase III trial for B-cell lymphoma (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top